TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27153942

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Psychoeducative Group Therapy (PeGT)
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (CGI-s and SOFAS)
Number of subjects: 1515
Study: 24776218

Group type: EXPERIMENTAL
Intervention: tranexamic acid 10 mg/kg body weight
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo saline 5 ml
Number of subjects: 49
Study: 22703642

Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20104071

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17432704

Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA (0.1 mmol/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 84
Study: 15629610

Group type: EXPERIMENTAL
Intervention: WBRT plus TMZ (75 mg/m²/d) plus two cycles of TMZ (200 mg/m²/d for 5 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: WBRT alone (30 Gy)
Number of subjects: 82
Study: 11966507

Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome (IBS)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Co-twin analyses of IBS
Number of subjects: 288
Study: 10369195

Group type: EXPERIMENTAL
Intervention: Chlorambucil in conjunction with oral steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and oral steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral high-dose corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0
Study: 7759773

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG) 400 mg/Kg every fourth week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral acyclovir 800 mg twice a day for one week every month
Number of subjects: 0
Study: 1969833

Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg bd
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30509370

Group type: EXPERIMENTAL
Intervention: octreotide-LAR
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 29725755

Group type: EXPERIMENTAL
Intervention: Moderately heavy-load exercise (70% 1RM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-load exercise with 80% arterial occlusion pressure (15/80)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-load exercise with 40% arterial occlusion pressure (15/40)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-load exercise with 0% arterial occlusion pressure (15/0)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-load exercise with 15% 1RM (15/0)
Number of subjects: 22
Study: 25663177

Group type: EXPERIMENTAL
Intervention: Urinary catheter self-efficacy (C-SE) scale
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Urinary catheter self-management (C-SMG) scale
Number of subjects: 202
Study: 24487666

Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise combined with cognitive training (12 sessions, 3 times a week for 4 weeks, 75 min each session)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mental relaxation training combined with cognitive training (12 sessions, 3 times a week for 4 weeks, 75 min each session)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise
Number of subjects: 51
Study: 22176295

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte drink
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 9
Study: 20486419

Group type: EXPERIMENTAL
Intervention: Run-in periods in clinical trials
Number of subjects: 0
Study: 18173142

Group type: EXPERIMENTAL
Intervention: Liuwu Shengjing Decoction (LWD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Wuzi Yanzong Pill (WYP)
Number of subjects: 114
Study: 15886446

Group type: EXPERIMENTAL
Intervention: Masimo SET Rad-9 oximeter
Number of subjects: 9

Group type: COMPARATOR
Intervention: Novametrix Oxypleth oximeter
Number of subjects: 9
Study: 12072067

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2% (2 mL day-1) plus combined oral contraceptive
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cyproterone acetate (52 mg day-1) plus ethinyl oestradiol (35 microg for 20 of every 28 days)
Number of subjects: 66
Study: 9797104

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (20 cigarettes per day for at least 2 years)
Number of subjects: 25
Study: 10152782

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ceftazidime 2 g q8h
Number of subjects: 106
Study: 2677916

Group type: EXPERIMENTAL
Intervention: Conservative functional treatment with orthotic support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operative functional treatment
Number of subjects: 0
Study: 416763

Group type: EXPERIMENTAL
Intervention: Glucagon hydrochloride (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oxyphenonium bromomethylate (group B)
Number of subjects: 62
Study: 31984480

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 593
Study: 31116262

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) combined with music therapy (MT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 101
Study: 28270029

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waitlist-control group (no treatment)
Number of subjects: 67
Study: 25874853

Group type: EXPERIMENTAL
Intervention: Sildenafil (2 × 20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 18
Study: 24238512

Group type: EXPERIMENTAL
Intervention: Famitinib (13-30 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Famitinib (25 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Famitinib
Number of subjects: 24
Study: 22035131

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/losartan 50 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/losartan 50 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 148
Study: 17956153

Group type: EXPERIMENTAL
Intervention: Abdominal aortic calcification scored on VFA images using a 24-point scale
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Abdominal aortic calcification scored on VFA images using an 8-point scale
Number of subjects: 816
Study: 15705666

Group type: EXPERIMENTAL
Intervention: Training intervention consisting of four modules delivered by a trained facilitator using videotapes and interactive exercises.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 101
Study: 12445221

Group type: EXPERIMENTAL
Intervention: Toothpaste with higher RDA value
Number of subjects: 10

Group type: COMPARATOR
Intervention: Toothpaste with lower RDA value
Number of subjects: 10
Study: 10350494

Group type: EXPERIMENTAL
Intervention: Formulation containing 5% flurbiprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formulation (0% flurbiprofen)
Number of subjects: 0
Study: 7851558

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (CDDP 66 mg/m2 x 1, ADM 26 mg/m2 x 1, UFT 8 mg/kg/day for 6 months)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (after adjusting for pN)
Number of subjects: 309
Study: 1779485

Group type: EXPERIMENTAL
Intervention: 0.12% UF-021, single instillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.12% UF-021, twice daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.12% UF-021, single and long-term use
Number of subjects: 0
Study: 7032532

Group type: EXPERIMENTAL
Intervention: Plafibride (N‐2‐(p‐chlorophenoxy)‐isobutyryl‐N'‐morpholinomethylurea, ITA 104)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 0
Study: 31060476

Group type: EXPERIMENTAL
Intervention: GABA Oolong tea
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High L-Theanine tea
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo tea (low GABA)
Number of subjects: 9
Study: 29653550

Group type: EXPERIMENTAL
Intervention: 1.6 g of Mecasin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2.4 g of Mecasin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Standard treatment with 100 mg of riluzole
Number of subjects: 36
Study: 28199752

Group type: EXPERIMENTAL
Intervention: Subcostal TAP block in combination with general anesthesia
Number of subjects: 49

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 49
Study: 26233509

Group type: EXPERIMENTAL
Intervention: JNJ-40346527 100 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 24142206

Group type: EXPERIMENTAL
Intervention: Odanacatib (3 once-weekly doses of 50 mg) co-administered with warfarin (30 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Warfarin (30 mg) alone
Number of subjects: 13
Study: 21134325

Group type: COMPARATOR
Intervention: Calcium HMB (CaHMB) - gelatin capsule, 1 g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HMB free acid gel swallowed (FASW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HMB free acid gel held sublingual for 15 s then swallowed (FASL)
Number of subjects: 8
Study: 18211121

Group type: EXPERIMENTAL
Intervention: Apricitabine 200 mg twice daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Apricitabine 400 mg twice daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Apricitabine 600 mg twice daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Apricitabine 800 mg twice daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Apricitabine 800 mg once daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Apricitabine 1200 mg once daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16629939

Group type: EXPERIMENTAL
Intervention: Cernevit (vitamin preparation with glycocholic acid)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control vitamin supplements
Number of subjects: 74
Study: 15323062

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg)/Indapamide (0.625 mg)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 214
Study: 11260239

Group type: EXPERIMENTAL
Intervention: Moisturizer 1 (lipid-rich)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moisturizer 2 (lipid-rich)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moisturizer 3 (lipid-rich)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moisturizer 4 (less lipid-rich)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moisturizer 5 (less lipid-rich)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moisturizer 6 (less lipid-rich)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 36
Study: 9032174

Group type: EXPERIMENTAL
Intervention: Amino acids and related compounds in bronchoalveolar lavage (BAL) fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study: 8500246

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 1446

Group type: COMPARATOR
Intervention: No warfarin treatment
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Patients experiencing thromboembolic events
Number of subjects: 1446
Study: 3548616

Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin at midnight before the operation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin and 75 mg of dipyridamole at midnight and an additional 75 mg of dipyridamole at 6 AM
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 29241713

Group type: EXPERIMENTAL
Intervention: Superficial heating (hot packs) applied for 30 minutes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Superficial heating (hot packs) with insulation maintained for an additional 30 minutes
Number of subjects: 21
Study: 27528062

Group type: EXPERIMENTAL
Intervention: Achieved automated office BP at baseline
Number of subjects: 6183

Group type: EXPERIMENTAL
Intervention: Pulse pressure at ≥80 mm Hg
Number of subjects: 6183
Study: 25483635

Group type: EXPERIMENTAL
Intervention: Zagreb regimen (2-1-1)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Essen regimen
Number of subjects: 825
Study: 22929263

Group type: EXPERIMENTAL
Intervention: Microvascular TRAM flap with single-nerve anastomosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microvascular TRAM flap with double-nerve anastomosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microvascular TRAM flap with no nerve dissection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All surgical techniques (including microvascular TRAM flap)
Number of subjects: 60
Study: 20084540

Group type: EXPERIMENTAL
Intervention: Proliferative lesions without atypia
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Atypical hyperplasia
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Multiple foci of columnar cell hyperplasia and complex fibroadenoma without atypia
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Sclerosing adenosis, radial scar, and papilloma
Number of subjects: 1239
Study: 18701886

Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Total buprenorphine meconium concentrations and buprenorphine/norbuprenorphine ratios
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Free buprenorphine concentration and percentage free buprenorphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thrice‐weekly urine tests for opiates, cocaine, and benzodiazepines
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buprenorphine and metabolite concentrations in meconium
Number of subjects: 10
Study: 15795438

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 689
Study: 12846271

Group type: EXPERIMENTAL
Intervention: HRT group (n = 151) received a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Number of subjects: 331

Group type: COMPARATOR
Intervention: Non-HRT group (n = 180) received 93 mg calcium alone or in combination with vitamin D3 (100-300 IU/day)
Number of subjects: 331
Study: 10975887

Group type: EXPERIMENTAL
Intervention: Thiopental anesthesia
Number of subjects: 12
Study: 8970354

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8245327

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Immediate intravenous metoprolol
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Protocol angiography 18 to 48 hours after rt-PA
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Survival to 21 days
Number of subjects: 2546
Study: 3915317

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 140

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 140
Study: 29439773

Group type: EXPERIMENTAL
Intervention: Desensitizing gel with 5% potassium nitrate and 5% glutaraldehyde
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo control gel
Number of subjects: 42
Study: 27368057

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Continuous Training (MVCT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both HIIT and MVCT
Number of subjects: 31
Study: 24100412

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS (+sham tDCS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (+sham rTMS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation (sham rTMS+sham tDCS)
Number of subjects: 11
Study: 21339541

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA) 3 x 6 g/d for 2 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no LOLA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 19108985

Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Hierarchical model
Number of subjects: 1218
Study: 17898990

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3356

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3356
Study: 15557360

Group type: EXPERIMENTAL
Intervention: Patient partnership intervention (n = 107) received drug safety information and their medication list
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (n = 102) received drug safety information only
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Patient partnership intervention (n = 107)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Nurse respondents
Number of subjects: 209
Study: 11567990

Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF) alone for 4 days at 10 microg/kg per day (arm A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cyclophosphamide (5 g/m(2)) and G-CSF at 10 microg/kg per day until hematologic recovery (arm B)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 47
Study: 9633797

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study: 7880511

Group type: COMPARATOR
Intervention: Droperidol-fentanyl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midazolam-fentanyl
Number of subjects: 20
Study: 3046772

Group type: EXPERIMENTAL
Intervention: Ivermectin 100, 150 and 200 micrograms/kg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 31128336

Group type: EXPERIMENTAL
Intervention: Infliximab treatment with trough concentrations greater than 23.1 mg/L at week 2
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Infliximab treatment with trough concentrations greater than 10.0 mg/L at week 6
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Infliximab maintenance therapy with trough concentrations greater than 10.6 mg/L
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Low fecal concentrations of calprotectin during therapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Persistent increase in fecal concentration of calprotectin despite dose escalation
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Patients with antibodies to infliximab
Number of subjects: 122
Study: 29886103

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/12h
Number of subjects: 80

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 80
Study: 28586262

Group type: EXPERIMENTAL
Intervention: Continuous venovenous diahemofiltration (CVVDH)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Laparoscopic peritoneal lavage and drainage (LPLD)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: LPLD + CVVDH
Number of subjects: 245

Group type: COMPARATOR
Intervention: Basic treatment
Number of subjects: 245
Study: 24299075

Group type: EXPERIMENTAL
Intervention: Implicit self-esteem measures
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Explicit self-esteem measures
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Explicit prime
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Prime meant to activate self-competence related implicit attitudes
Number of subjects: 1008
Study: 23262750

Group type: EXPERIMENTAL
Intervention: Plasma 25(OH)D
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Plasma 1,25(OH)2D
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: VDR BsmI polymorphism
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: VDR FokI polymorphism
Number of subjects: 1211
Study: 20932651

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with concurrent temozolomide (TMZ) chemotherapy, 60 Gy total dose, escalating from 3 Gy/fraction to 6 Gy/fraction, concurrent TMZ at 75 mg/m²/d for 28 days, adjuvant TMZ at 150-200 mg/m²/d for 5 days every 28 days.
Number of subjects: 16
Study: 18094325

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 21251026

Group type: EXPERIMENTAL
Intervention: Early reablation (ERe+) at 28.1 ± 2.7 days postablation
Number of subjects: 375

Group type: COMPARATOR
Intervention: Nonearly reablation (ERe-) at 98.2 ± 5.2 days postablation
Number of subjects: 375